JP2014516954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516954A5 JP2014516954A5 JP2014510502A JP2014510502A JP2014516954A5 JP 2014516954 A5 JP2014516954 A5 JP 2014516954A5 JP 2014510502 A JP2014510502 A JP 2014510502A JP 2014510502 A JP2014510502 A JP 2014510502A JP 2014516954 A5 JP2014516954 A5 JP 2014516954A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic composition
- steroid
- group
- concentration
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 49
- 150000003431 steroids Chemical class 0.000 claims 16
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims 10
- 229920000153 Povidone-iodine Polymers 0.000 claims 9
- 229960001621 povidone-iodine Drugs 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 239000011630 iodine Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 4
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 4
- 229960001067 hydrocortisone acetate Drugs 0.000 claims 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 4
- 206010023332 keratitis Diseases 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 4
- 229960004224 tyloxapol Drugs 0.000 claims 4
- 229920001664 tyloxapol Polymers 0.000 claims 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 3
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 3
- 229950009769 etabonate Drugs 0.000 claims 3
- 239000003589 local anesthetic agent Substances 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 3
- 235000011152 sodium sulphate Nutrition 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- 241000224489 Amoeba Species 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 206010023335 Keratitis interstitial Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims 2
- 229960003655 bromfenac Drugs 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 229960004875 difluprednate Drugs 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 201000006904 interstitial keratitis Diseases 0.000 claims 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 2
- 229960003744 loteprednol etabonate Drugs 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 201000003826 superficial keratitis Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 229920002057 Pluronic® P 103 Polymers 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- -1 diflupredonate Chemical compound 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 229940067107 phenylethyl alcohol Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229960003981 proparacaine Drugs 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229940033663 thimerosal Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161485475P | 2011-05-12 | 2011-05-12 | |
| US61/485,475 | 2011-05-12 | ||
| PCT/US2012/037563 WO2012155062A1 (en) | 2011-05-12 | 2012-05-11 | Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248924A Division JP6359619B2 (ja) | 2011-05-12 | 2016-12-22 | ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516954A JP2014516954A (ja) | 2014-07-17 |
| JP2014516954A5 true JP2014516954A5 (enExample) | 2015-06-25 |
| JP6072009B2 JP6072009B2 (ja) | 2017-02-01 |
Family
ID=47139697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510502A Expired - Fee Related JP6072009B2 (ja) | 2011-05-12 | 2012-05-11 | ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物 |
| JP2016248924A Expired - Fee Related JP6359619B2 (ja) | 2011-05-12 | 2016-12-22 | ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248924A Expired - Fee Related JP6359619B2 (ja) | 2011-05-12 | 2016-12-22 | ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150038473A1 (enExample) |
| EP (1) | EP2707006B1 (enExample) |
| JP (2) | JP6072009B2 (enExample) |
| KR (1) | KR101967938B1 (enExample) |
| CN (1) | CN103957922A (enExample) |
| AR (1) | AR086399A1 (enExample) |
| AU (3) | AU2012253335B2 (enExample) |
| BR (1) | BR112013028735A2 (enExample) |
| CA (1) | CA2835343A1 (enExample) |
| CL (1) | CL2013003016A1 (enExample) |
| CO (1) | CO6821949A2 (enExample) |
| EC (1) | ECSP13013069A (enExample) |
| MX (1) | MX360666B (enExample) |
| PE (1) | PE20141070A1 (enExample) |
| TW (2) | TWI717552B (enExample) |
| WO (1) | WO2012155062A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2665195B2 (ja) | 1995-05-19 | 1997-10-22 | 日本電気移動通信株式会社 | Ｍｃａシステムにおける移動局の個別番号表示方法 |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| TW201808311A (zh) * | 2011-09-16 | 2018-03-16 | 遠景生物製藥股份有限公司 | 安定之普維酮-碘組成物 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| KR102154880B1 (ko) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| KR20150119303A (ko) | 2013-02-15 | 2015-10-23 | 센주 세이야꾸 가부시키가이샤 | 항균성 금속을 함유하는 디플루프레드네이트 유액 조성물 |
| EP2958895B1 (en) | 2013-02-20 | 2020-08-19 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA2928658A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| LT3416654T (lt) | 2016-02-18 | 2022-01-10 | Invirsa, Inc. | 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas |
| EP3442519A4 (en) | 2016-04-14 | 2019-12-04 | Azura Opthalmics Ltd. | SELDISULFID COMPOSITIONS FOR USE IN THE TREATMENT OF THE MEIBOM DRESSING DYSFUNCTION |
| CA3023259A1 (en) * | 2016-05-05 | 2017-11-09 | Veloce Biopharma, Llc | Compositions and methods for treatment of inflammation or infection of the eye |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR101935250B1 (ko) * | 2017-07-04 | 2019-01-04 | 김대황 | 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
| ES2949441T3 (es) | 2018-03-27 | 2023-09-28 | Invirsa Inc | Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR) |
| CN115279458A (zh) | 2020-01-10 | 2022-11-01 | 阿祖拉眼科有限公司 | 组合物和敏感性说明 |
| CN113797164B (zh) * | 2020-06-17 | 2023-07-14 | 成都瑞沐生物医药科技有限公司 | 一种眼用制剂的载体或辅料及其制备方法和应用 |
| CN112305115B (zh) * | 2020-10-29 | 2022-08-23 | 诺峰药业(成都)有限公司 | 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法 |
| KR20220062790A (ko) | 2020-11-09 | 2022-05-17 | 정춘영 | 포비돈 아이오딘계 소독액 |
| KR102489633B1 (ko) * | 2021-01-21 | 2023-01-17 | 주식회사태준제약 | 점안 조성물 |
| JP2024507326A (ja) * | 2021-01-22 | 2024-02-19 | チョンドゥー ルイムー バイオファーマスーティカルズ カンパニー リミテッド | 点眼投与により乾燥型黄斑変性症および網膜光障害を予防・治療するための眼科用製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886268A (en) | 1972-05-30 | 1975-05-27 | Synergistics | Iodophor-steroid compound pharmaceutical compositions |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| NZ625086A (en) * | 2008-06-12 | 2015-11-27 | Foresight Biotherapeutics Inc | Povidone iodine, a novel alternative preservative for ophthalmic compositions |
| JP2013514373A (ja) * | 2009-12-15 | 2013-04-25 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | 非刺激性の眼科用ポビドンヨード組成物 |
| TW201808311A (zh) * | 2011-09-16 | 2018-03-16 | 遠景生物製藥股份有限公司 | 安定之普維酮-碘組成物 |
-
2012
- 2012-05-11 MX MX2013012971A patent/MX360666B/es active IP Right Grant
- 2012-05-11 CA CA2835343A patent/CA2835343A1/en not_active Abandoned
- 2012-05-11 JP JP2014510502A patent/JP6072009B2/ja not_active Expired - Fee Related
- 2012-05-11 BR BR112013028735A patent/BR112013028735A2/pt not_active Application Discontinuation
- 2012-05-11 EP EP12781920.9A patent/EP2707006B1/en active Active
- 2012-05-11 TW TW106131033A patent/TWI717552B/zh not_active IP Right Cessation
- 2012-05-11 KR KR1020137032559A patent/KR101967938B1/ko not_active Expired - Fee Related
- 2012-05-11 US US14/117,086 patent/US20150038473A1/en not_active Abandoned
- 2012-05-11 AU AU2012253335A patent/AU2012253335B2/en not_active Ceased
- 2012-05-11 TW TW101116855A patent/TWI632914B/zh not_active IP Right Cessation
- 2012-05-11 CN CN201280034191.2A patent/CN103957922A/zh active Pending
- 2012-05-11 WO PCT/US2012/037563 patent/WO2012155062A1/en not_active Ceased
- 2012-05-11 PE PE2013002407A patent/PE20141070A1/es not_active Application Discontinuation
- 2012-05-14 AR ARP120101708A patent/AR086399A1/es not_active Application Discontinuation
-
2013
- 2013-10-17 CL CL2013003016A patent/CL2013003016A1/es unknown
- 2013-12-09 CO CO13287528A patent/CO6821949A2/es not_active Application Discontinuation
- 2013-12-09 EC ECSP13013069 patent/ECSP13013069A/es unknown
-
2016
- 2016-09-02 AU AU2016222491A patent/AU2016222491A1/en not_active Abandoned
- 2016-12-22 JP JP2016248924A patent/JP6359619B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-17 AU AU2018203492A patent/AU2018203492A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516954A5 (enExample) | ||
| JP2020196718A5 (enExample) | ||
| JP6539444B2 (ja) | 安定なポビドンヨード組成物 | |
| CN101400355B (zh) | 包含聚维酮碘的眼用组合物 | |
| TWI620569B (zh) | 無刺激性眼用聚乙烯吡咯啶酮-碘組成物 | |
| JP6527341B2 (ja) | ポビドンヨード、眼科用組成物のための新規代替保存剤 | |
| JP5714512B2 (ja) | 哺乳動物の内耳及び外耳の感染症の治療に有用な耳科用組成物 | |
| JP2011006448A (ja) | 第四級化アンモニウムシクロデキストリン化合物 | |
| JP2013518056A5 (enExample) | ||
| JP2019515040A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| AU2017235979B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
| NZ751915B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
| HK1197970A (en) | Stable povidone-iodine compositions |